Treatment with intrathecal colistin of a resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae in the cerebrospinal fluid

Infectious Diseases in Clinical Practice

Volumn 15, Issue 4, 2007, Pages 274-277

  Enfanto, Christopher M ^a   Shin, Sonya ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; COLISTIN; MEROPENEM; METRONIDAZOLE; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BONE GRAFT; CASE REPORT; CEREBROSPINAL FLUID; FEMUR FRACTURE; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE INFECTION; TREATMENT DURATION;

EID: 34447559520     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e31802df0d7     Document Type: Article

References (16)

1. Kearney B, Aweeka F. The penetration of anti-infectives into the central nervous system. Neurol Clin. 1999;17:883-900.
2. Lustar I, McCracken GH, Friedland I. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis. 1998;27:1117-1129.
3. Davis SE, Levy ML, McComb JG, et al. Does age or other factors influence the incidence of ventriculoperitoneal shunt infections? Pediatr Neurosurg. 1999;30:253-257.
4. George R, Leibrock L, Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg. 1979;51:804-811.
5. Schoenbaum SC, Gardner P, Shillito J. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis. 1975;131:543-552.
6. Berlina D, Llop E, Fort MB, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm. 2005;62:39-47.
7. Weinbren MJ, Borthwick MA. Rapid detection of extended-spectrum β-lactamase (ESBL)-producing organisms in blood culture. J Antimicrob Chemother. 2005;55:131-132.
8. Falagas M, Kasiakou S. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333-1340.
9. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72:857-868.
10. Price DJ, Graham DI. Effects of large doses of colistin sulphomethate sodium on renal dysfunction. Br Med J. 1970;4:525-527.
11. Randall RE, Bridi GS, Setter JG, et al. Recovery from colisthemate nephrotoxicity. Ann Intern Med. 1970;73:491-492.
12. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure. Dosing Guidelines for Adults. 4th ed. Philadelphia, PA: American College of Physicians; 1999.
13. Fernandez-Viladrich P, Corbella X, Corral L, et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis. 1999;28:916-917.
14. Vasen W, Desmery P, Di Martineo A. Intrathecal use of colistin. J Clin Microbiol. 2000;38:3523. [letter].
15. Gump WC, Walsh JW. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis: case report and review of the literature. J Neurosurg. 2005;102:915-917.
16. Quinn AL, Parada JP, Belmares J, et al. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann Pharmacother. 2005;39:949-952.